PL1718322T3 - Synergistyczne kompozycje z fk-228 - Google Patents

Synergistyczne kompozycje z fk-228

Info

Publication number
PL1718322T3
PL1718322T3 PL05719967T PL05719967T PL1718322T3 PL 1718322 T3 PL1718322 T3 PL 1718322T3 PL 05719967 T PL05719967 T PL 05719967T PL 05719967 T PL05719967 T PL 05719967T PL 1718322 T3 PL1718322 T3 PL 1718322T3
Authority
PL
Poland
Prior art keywords
antitumor agent
antitumor
synergistic compositions
agent
dna
Prior art date
Application number
PL05719967T
Other languages
English (en)
Inventor
Yoshinori Naoe
Takeshi Inoue
Yasuhiko Kano
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of PL1718322T3 publication Critical patent/PL1718322T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL05719967T 2004-02-25 2005-02-25 Synergistyczne kompozycje z fk-228 PL1718322T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2004050520 2004-02-25
US56607704P 2004-04-29 2004-04-29
EP05719967A EP1718322B1 (en) 2004-02-25 2005-02-25 Synergistic compositions with fk-228
PCT/JP2005/003689 WO2005079827A2 (en) 2004-02-25 2005-02-25 Antitumor agent

Publications (1)

Publication Number Publication Date
PL1718322T3 true PL1718322T3 (pl) 2011-12-30

Family

ID=34889383

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05719967T PL1718322T3 (pl) 2004-02-25 2005-02-25 Synergistyczne kompozycje z fk-228

Country Status (11)

Country Link
US (2) US7951780B2 (pl)
EP (1) EP1718322B1 (pl)
JP (1) JP4930055B2 (pl)
AT (1) ATE516041T1 (pl)
CA (1) CA2557540A1 (pl)
CY (1) CY1111926T1 (pl)
DK (1) DK1718322T3 (pl)
PL (1) PL1718322T3 (pl)
PT (1) PT1718322E (pl)
SI (1) SI1718322T1 (pl)
WO (1) WO2005079827A2 (pl)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2298414C2 (ru) * 2001-08-21 2007-05-10 Астеллас Фарма Инк. Медицинское применение ингибитора гистоновой дезацетилазы и способ оценки его противоопухолевого действия
EP1492596A1 (en) * 2002-04-05 2005-01-05 Fujisawa Pharmaceutical Co., Ltd. Depsipeptide for therapy of kidney cancer
WO2004074478A1 (ja) * 2003-02-19 2004-09-02 Astellas Pharma Inc. ヒストンデアセチラーゼ阻害剤の抗腫瘍効果の予測方法
DE602004027824D1 (de) * 2003-09-25 2010-08-05 Astellas Pharma Inc Antitumorales mittel mit einem histon-deacetylase-hemmer und einem topoisomerase-ii-hemmer
US7951780B2 (en) 2004-02-25 2011-05-31 Astellas Pharma Inc. Antitumor agent
CA2627129A1 (en) * 2005-11-04 2007-05-18 Merck & Co., Inc. Methods of using saha and bortezomib for treating cancer
CA2630216A1 (en) * 2005-11-18 2007-05-31 Gloucester Pharmaceuticals, Inc. Metabolite derivatives of the hdac inhibitor fk228
US9539303B2 (en) * 2006-04-24 2017-01-10 Celgene Corporation Treatment of Ras-expressing tumors
US8957027B2 (en) * 2006-06-08 2015-02-17 Celgene Corporation Deacetylase inhibitor therapy
NZ575388A (en) * 2006-10-06 2012-03-30 Bn Immunotherapeutics Inc Recombinant modified vaccinia ankara encoding a her-2 antigen and a taxane for use in treating cancer
CN103497238A (zh) * 2006-12-29 2014-01-08 细胞基因公司 制备Romidepsin
EP2102230A2 (en) * 2006-12-29 2009-09-23 Gloucester Pharmaceuticals, Inc. Purifiction of romidepsin
US9156792B2 (en) * 2008-05-09 2015-10-13 University Of Maryland, Baltimore Retinamide and uses thereof
EP2366398A1 (en) * 2010-03-17 2011-09-21 Deutsches Krebsforschungszentrum Cancer therapy with a parvovirus combined with an HDAC inhibitor
CA2801891C (en) * 2010-06-07 2020-10-27 Abraxis Bioscience, Llc Combination therapy methods for treating proliferative diseases
CN103108648A (zh) 2010-07-12 2013-05-15 细胞基因公司 罗米地辛固体形式及其用途
US8859502B2 (en) 2010-09-13 2014-10-14 Celgene Corporation Therapy for MLL-rearranged leukemia
AU2013202506B2 (en) 2012-09-07 2015-06-18 Celgene Corporation Resistance biomarkers for hdac inhibitors
AU2013202507B9 (en) 2012-11-14 2015-08-13 Celgene Corporation Inhibition of drug resistant cancer cells
NZ630311A (en) 2013-12-27 2016-03-31 Celgene Corp Romidepsin formulations and uses thereof
CN106860872B (zh) * 2017-01-18 2019-03-22 上海交通大学 用于逆转肿瘤对铂类抗癌药多药耐药性的两亲性药-药纳米颗粒药物及其制备方法与应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8817743D0 (en) * 1988-07-26 1988-09-01 Fujisawa Pharmaceutical Co Fr901228 substance & preparation thereof
JPH0315810A (ja) * 1989-06-13 1991-01-24 Minolta Camera Co Ltd カメラ
US6252058B1 (en) * 1997-11-05 2001-06-26 Timothy C. Thompson Sequences for targeting metastatic cells
IL149363A0 (en) * 1999-11-10 2002-11-10 Warner Lambert Co Combination chemotherapy
EP1246839B1 (en) * 1999-12-08 2004-06-16 Xcyte Therapies, Inc. Depsipeptide and congeners thereof for use as immunosuppressants
ATE425177T1 (de) 2000-07-17 2009-03-15 Astellas Pharma Inc Reduziertes fk228 und seine verwendung
US7396665B2 (en) 2000-09-01 2008-07-08 Astellas Pharma, Inc. Method of producing FR901228
DK1355566T3 (da) * 2000-12-18 2013-03-04 Univ Texas Lokal regional kemoterapi og radioterapi ved anvendelse af hydrogel in situ
US6905669B2 (en) * 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
US6620816B2 (en) * 2001-04-26 2003-09-16 Bristol-Myers Squibb Company Method for treating tumors by the administration of tegafur, uracil, folinic acid, and cyclophosphamide
RU2298414C2 (ru) 2001-08-21 2007-05-10 Астеллас Фарма Инк. Медицинское применение ингибитора гистоновой дезацетилазы и способ оценки его противоопухолевого действия
EP1429764A1 (en) * 2001-08-31 2004-06-23 Bristol-Myers Squibb Company Compositions and methods for the treatment of cancer
EP1293205A1 (en) 2001-09-18 2003-03-19 G2M Cancer Drugs AG Valproic acid and derivatives thereof for the combination therapy of human cancers, for the treatment of tumour metastasis and minimal residual disease
EP1492596A1 (en) * 2002-04-05 2005-01-05 Fujisawa Pharmaceutical Co., Ltd. Depsipeptide for therapy of kidney cancer
JP2005530734A (ja) 2002-04-15 2005-10-13 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ 癌の処置のための併用療法
PA8578001A1 (es) * 2002-08-07 2004-05-07 Warner Lambert Co Combinaciones terapeuticas de inhibidores de quinasa de erb b y terapias antineoplasicas
WO2004064727A2 (en) 2003-01-16 2004-08-05 Georgetown University Method of cancer treatment using hdac inhibitors
WO2004074478A1 (ja) 2003-02-19 2004-09-02 Astellas Pharma Inc. ヒストンデアセチラーゼ阻害剤の抗腫瘍効果の予測方法
EP1638541B1 (en) * 2003-06-27 2010-05-19 Astellas Pharma Inc. Therapeutic agent for soft tissue sarcoma
CA2472842C (en) 2003-07-22 2012-05-29 Honda Motor Co., Ltd. Working machine
DE602004027824D1 (de) * 2003-09-25 2010-08-05 Astellas Pharma Inc Antitumorales mittel mit einem histon-deacetylase-hemmer und einem topoisomerase-ii-hemmer
US20050187148A1 (en) 2004-02-25 2005-08-25 Yoshinori Naoe Antitumor agent
US7951780B2 (en) 2004-02-25 2011-05-31 Astellas Pharma Inc. Antitumor agent

Also Published As

Publication number Publication date
SI1718322T1 (sl) 2011-09-30
US8822422B2 (en) 2014-09-02
US20110160295A1 (en) 2011-06-30
DK1718322T3 (da) 2011-08-29
CY1111926T1 (el) 2015-11-04
CA2557540A1 (en) 2005-09-01
US20050187149A1 (en) 2005-08-25
EP1718322B1 (en) 2011-07-13
JP2007524650A (ja) 2007-08-30
US7951780B2 (en) 2011-05-31
WO2005079827A3 (en) 2005-12-08
ATE516041T1 (de) 2011-07-15
PT1718322E (pt) 2011-09-05
EP1718322A2 (en) 2006-11-08
WO2005079827A2 (en) 2005-09-01
JP4930055B2 (ja) 2012-05-09

Similar Documents

Publication Publication Date Title
PT1718322E (pt) Composições sinérgicas com fk-228
MXPA06003222A (es) Agente antitumoral que comprende un inhibidor de histona desacetilasa y un inhibidor de topoisomerasa ii.
WO2007103719A3 (en) MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
WO2007126832A3 (en) Pharmaceutical compositions for prevention of overdose or abuse
MX2008010801A (es) Indolopiridinas como moduladores de quinesina eg5.
WO2007064945A3 (en) Cancer therapies and pharmaceutical compositions used therein
NO20073026L (no) 2-alkoksy-3,4,5-trihydroksy-alkylamider, fremstilling og sammensetninger derav samt anvendelse derav
WO2007095258A3 (en) Rhamnolipid compositions and related methods of use
MY140514A (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
WO2007054573A3 (en) Anti-proliferative combination therapy comprising a platinum-based chemotherapeutic agent and egfr inhibitors or pyrimidine analogues
MX2007014920A (es) Politerapia que comprende diarilureas para el tratamiento de enfermedades.
GB2437149B (en) Synergistic preservative systems and their use in cosmetic compositions.
WO2006061258A3 (en) Cytotoxic agents comprising new taxanes
WO2007030409A3 (en) In-can and dry coating antimicrobial compositions having hydroxy analogs of methionine and derivatives
IL183481A (en) Combinations containing vegf-trap with 5-fluorouracil are useful in the treatment of neoplastic diseases
WO2007124382A3 (en) Inhaled imipenem
IL178727A0 (en) Tetrahydropyridothiophene derivatives and pharmaceutical compositions containing the same
WO2006061259A3 (en) Cytotoxic agents comprising new c-2 modified taxanes
PL1591514T3 (pl) Zastosowanie dodatków do poprawy zapachu kompozycji węglowodorów oraz kompozycje węglowodorów zawierające takie dodatki
WO2009047434A3 (fr) Utilisation d'excipients en tant que conservateurs et composition pharmaceutique les comprenant
EP2357003A4 (en) COMPOSITION AGAINST CANCER WITH AN ANTI-TUMOR ACTIVE SUBSTANCE AND A SUBSTANCE CONDENSING THE L1CAM ACTIVITY AND EXPRESSION
SI1883647T1 (sl) Oligonukleotid in obsegajoča ga sestava za zdravljenje B celične neoplazme
TW200503676A (en) Use of kynurenine 3-hydroxylase inhibitors for the treatment of diabetes
WO2007044325A3 (en) Apoe4 domain interaction inhibitors and methods of use thereof
MY139425A (en) Pharmaceutical composition comprising 2,4-dichlorobenzyl alcohol and amylmetacresol